Repligen Corp (RGEN) Valuation
Historical valuation analysis based on 500 data points (2024-09-27 to 2026-09-25)
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, includ...
Repligen Corp (RGEN) currently trades at a P/E ratio of 209.13 (historical range: 0.04–210.19, median: 5.28), placing it at the 99th percentile — expensive relative to its history, P/S ratio of 14.08 (range: 0.01–14.15, 100th percentile — expensive relative to its history), EV/EBITDA of 162.88 (range: 86.65–163.73, 98th percentile).
Over the historical period (2024-09-27 to 2026-09-25), Repligen Corp's P/E ratio has expanded by 184404% over the observed period (from an average of 0.0 to 80.2).
Repligen Corp trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 209.13 | 0.04 | 5.28 | 210.19 | 99th | expensive relative to its history |
| P/S Ratio | 14.08 | 0.01 | 0.01 | 14.15 | 100th | expensive relative to its history |
| EV/EBITDA | 162.88 | 86.65 | 116.62 | 163.73 | 98th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 12.87 | 24.31 | 0th | expensive relative to its history |
Repligen Corp (RGEN) Valuation & P/E History
Repligen Corp (RGEN) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $189.68 with a market capitalization of $10.7 billion. This page provides historical valuation analysis for RGEN based on 500 data points covering 2024-09-27 to 2026-09-25. The P/E ratio of 209.13 is above the historical median of 5.28, placing RGEN at the 99th percentile of its valuation range. The P/S ratio of 14.08 compares to a median of 0.01.
RGEN Valuation Metrics & Historical Range
The valuation table above shows Repligen Corp's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether RGEN is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests RGEN is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Repligen Corp.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is RGEN Overvalued or Undervalued?
Repligen Corp trades well above its own historical valuation range across most metrics. The overall valuation percentile of 99 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive RGEN is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full RGEN analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.RGEN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.